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Abstract
Respiratory Syncytial Virus infections are one of the leading causes of severe respiratory diseases that require
hospitalization and, in some cases, intensive care. Once resolved, there may be respiratory sequelae of varying
severity. The lack of effective treatments for bronchiolitis and the lack of vaccines for RSV accentuate the role of
prevention in decreasing the impact of this disease.
Prevention of bronchiolitis strongly relies on the adoption of environment and the hygienic behavior measures; an
additional prophylactic effect may be offered, in selected cases, by Palivizumab, a humanized monoclonal antibody
produced by recombinant DNA technology, able to prevent RSV infection by blocking viral replication.
After many years the Italian Society of Neonatology, on the basis of the most recent scientific knowledge, has
decided to revise recommendations for the use of palivizumab in the prevention of RSV infection.
Background
Respiratory Syncytial Virus infections are one of the
leading causes of severe respiratory diseases that require
hospitalization and, in some cases, intensive care. Once
resolved, there may be respiratory sequelae of varying
severity.
Elements of virology
The respiratory syncytial virus (RSV) was isolated for
the first time in 1955 in a monkey. In man, the virus
was described in 1957 in two neonates presenting with
an airway infection [1].
It belongs to the order Monegavirales, family Paramyxo-
viridae, subfamily Pneumovirinae, genus Pneumovirus.
The RSV virion consists of a helical symmetrical
nucleocapsid surrounded by a lipid envelope, normally
derived from the host cell, and it contains three trans-
membrane glycoproteins shaped like short spikes on its
surface. Although glycoprotein G is in charge of mediating
adhesion to the ciliated epithelium of the airways and
entry of RSV in the infected cell, it is not strictly necessary
nor sufficient to cause the disease. There are two antigenic
subgroups of RSV, A and B, which may be identified based
on the different conformation of glycoprotein G. Fusion F
protein instead maintains its sequence in the two sub-
groups and plays the crucial role of allowing viral
penetration in the cells via fusion of the viral envelope
with the cytoplasmic membrane. The third protein is a
small hydrophobic protein called SH, and is a viroporin
capable of modifying cell membrane permeability [2].
Once RSV has penetrated in the host cell (mediated by
glycoproteins G and F) viral genome transcription and
viral replication take place in the cytoplasm, where pro-
teins and viral RNA accumulate and peak 15–20 hours
after infection. At this point, the viral progeny may start
to be released from the cell and continue for approxi-
mately 48 hours, or until the cell has been completely
destroyed. This latter phase might be preceded by the
development of cell syncytia (major cytopathogenic
effect of the virus) [2, 3].
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Epidemiology, clinical aspects, long-term
complications
RSV is the most frequent cause of airway infections in
children under the age of 2 years , and bronchiolitis is
the main cause for hospitalization during the first year
of life (approximately 1 % of children in Europe and the
United States), with peak of hospitalization at 2 months
of age [4]. Children younger than 3 months or who present
with pre-existing risk factors (prematurity, bronchopul-
monary dysplasia, congenital heart diseases, immunodefi-
ciency, neuromuscular diseases) are especially at risk for
severe disease and hospitalization, sometime with the need
for admission to the intensive care unit. In industrialized
countries, bronchiolitis, caused by a viral infection during
the first year of life, continues to remain an important
cause of death [5]. In Italy, the epidemic season is between
November and March, with a peak in January – February,
as shown by Italian epidemiological studies [6].
The diagnosis of bronchiolitis is based on clinical
criteria: rhinorrhea and/or upper airway infection, a first
episode of respiratory distress with crackles and/or
wheezing, polypnea, use of accessory muscle and chest
retractions, difficulties in taking fluids and food, hypoxia
[7–9]. Children with acute bronchiolitis may present
with a wide range of clinical presentations that range
from mild respiratory distress to impending respiratory
failure. The immune response to the RSV infection in
children who develop bronchiolitis is characterized by
the presence of a major neutrophil-mediated inflamma-
tion of the airways.
Hospitalization in case of bronchiolitis is indicated in
presence of hypoxia (O2 saturation <90-92 % at ambient
air), moderate to severe respiratory distress, dehydration,
apnea. Other criteria to be taken into account are
gestational age as well as postnatal age, belonging to
categories at risk, abnormal state of consciousness
and responsiveness, decreased fluid intake (<50 % of
habitual intake), unfavorable social and environmental
factors. Neonates or infants with severe bronchiolitis
should be admitted to a Pediatric Intensive Care Unit if
presenting with respiratory failure, and severe impairment
of general conditions [9].
There is no evidence of efficacy for many of the ther-
apies commonly used to treat bronchiolitis (bronchodila-
tors, steroids, antibiotics) [7] and supportive treatment
(warm humidified oxygen, high flows and hydration) still
remains the approach recommended by the leading
international and national guidelines [7–9]. Recent stud-
ies suggest that nebulization of 3 % hypertonic saline so-
lution provides clinical benefit, however data in this
regard are conflicting [10–13]. Nebulized epinephrine
might be useful in the hospital setting, as a rescue agent
in severe disease [8]. The lack of effective treatments for
bronchiolitis and the lack of vaccines for RSV accentuate
the role of prevention in decreasing the impact of
this disease.
Infection can be consistently controlled by the application
of environmental, hygienic and sanitary measures to cut dif-
fusion of the virus to a minimum and on pharmacological
prophylaxis with administration of palivizumab during the
epidemic season to children at high risk [14, 15]. Environ-
mental prophylaxis, especially during the epidemic season,
is essential to decrease transmission of RSV in the hospital
and outpatient clinic settings, since it is easily spread
through the air carried by saliva droplets and via contact
with contaminated objects and surfaces (hands, clothing,
toys, medical instruments, kitchen utensils, etc.) on which
the virus may deposit and remain active for several hours.
Environmental prophylaxis is performed by frequent wash-
ing and decontamination of hands using alcohol-based
solutions, and by cleaning solid surfaces with water and dis-
infectants (alcohol-based detergents are preferable). In the
hospital or outpatient clinic setting, multiple-use medical
equipment (e.g., stethoscope) must also be decontaminated.
The use of disposable gloves and white coats by healthcare
operators who have contact with the patient is rec-
ommended as well. Thanks to compliance with these
recommendations, hospital–acquired RSV infections
have decreased by 39–50 % [16]. It is very important
that breast-feeding be recommended as it decreases
infectious respiratory morbidity [7, 9, 17]. Parent edu-
cation is furthermore essential to avoid exposure of
children to secondhand cigarette smoke, which increases
the risk of developing bronchiolitis and respiratory infec-
tions [7]. Also preventing exposure of the fetus to
maternal secondhand smoke during pregnancy is of
especially importance [7, 14, 15, 18].
Later respiratory outcomes of bronchiolitis
An RSV infection in infants, in particular in those who
required hospitalization, might interfere with the normal
development of the immune system and of the lungs, and
might be associated with an increased incidence of recurrent
bronchospasm in preschoolers, asthma, and with decreased
respiratory function in school-aged children [19, 20].
Recent follow-up studies conducted through adulthood
(18 and 30 years of age) have demonstrated that up
to 30-40 % of subjects who had been previously hos-
pitalized because of bronchiolitis suffer from asthma
and use anti-asthma drugs [21].
A recent randomized, double-blind, placebo-controlled
study demonstrated that prophylaxis with palivizumab
given to healthy preterm babies (33 – 35 weeks gesta-
tional age) is able to decrease by 61 % the number of
days with bronchospasm throughout the first year of life,
thus supporting the hypothesis of a direct damage
caused by the virus. No similar studies are available in
full-term children [22].
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Scope of the recommendations
The Recommendations drafted by the Italian Society of
Neonatology concerning palivizumab prophylaxis for re-
spiratory syncytial virus infection intends to provide a
shared operating guidelines, for a uniform prescription
on the basis of the most recent scientific knowledge.
The levels of evidence are indicated in the Table 1.
Environmental hygiene prevention
Strict adherence to infection-control practices is import-
ant to reduce the spread of RSV disease and can be
affective in containing respiratory virus epidemics or in
hospital wards: isolation, cohorting, social distancing,
restricting visitation by young children, barriers, per-
sonal protection, surgical masks, handwashing [23]. En-
couraging breast-feeding throughout the baby’s first year
of life, and avoiding exposure to secondhand smoke are
effective methods to decrease prevalence of the RSV
disease in the pediatric population.
[Level of evidence II – strength of recommendation A]
Palivizumab
Palivizumab (Synagis; Medimmune, Inc., Gaithersburg,
MD) [24] is a humanized monoclonal antibody (IgG1) pro-
duced by recombinant DNA technology, directed against
an epitope in the A antigenic site of the fusion F protein of
RSV. Palivizumab acts by inhibiting and neutralizing the fu-
sion action of the F protein, thus blocking viral replication.
The multicenter, randomized, double-blind, controlled
clinical study IMpact (RSV-IMpact trial) licensed in
1998 used palivizumab at the dosage of 15 mg/kg ad-
ministered via intramuscular injection once a month,
during the epidemic season, for a total of 5 administrations
[25]. Despite it being widely used for more than a decade,
only a study recently performed by Robbie et al. [26]
analyzed the various pharmacokinetic scenarios for
palivizumab in infants, children and adults with several
clinical presentations. The few previously conducted phar-
macokinetic studies only described mean serum concentra-
tions and half-life ranging between 17 [27] and 26.8 days
[28]. The manufacturing company itself, in 2012, indicated
a marked inter-individual variability in serum concen-
trations of palivizumab when administered as per the
registered regimen [24].
The study performed by Robbie et al. [26] also
assessed the impact on inter-individual variability of the
formation of antidrug antibodies (ADA) and of a number
of specific pathological conditions, to verify if an adequate
protection was ensured with only 3 administrations in-
stead of the contemplated 5 doses. The conclusions of the
study performed by Robbie highlighted a slight difference
in the pharmacokinetic profile between full-term and pre-
term neonates, and showed that 5 administrations during
the epidemic season guarantee greater and longer lasting
protection compared to the scheme with only 3 seasonal
administrations. These findings were confirmed by subse-
quent studies [29]. Therefore, the scheme which contem-
plates a monthly intramuscular administration at the
dosage of 15 mg/kg for 5 months, as indicated in the
registered scheme, would appear to be more appropriate.
[Level of evidence II – strength of recommendation A]
Palivizumab prophylaxis in preterm infants
The efficacy and safety profile of palivizumab was
proved by a multicenter, randomized, double-blind, con-
trolled clinical trial (RSV-IMpact trial) [25].
1502 preterm babies of ≤ 35 weeks gestational age
(GA) and ≤ 6 months of age at the beginning of the
Table 1 Level of evidence and strength of recommendation for RSV prophylaxis with palivizumab
Level of evidence
I evidence obtained by randomized controlled clinical studies and/or by systematic reviews of randomized studies
II evidence obtained from an individual and adequately designed randomized study
III evidence obtained by cohort studies with concurrent or historical controls, or a meta-analysis thereof.
IV evidence obtained by retrospective, case-controlled studies or meta-analysis
V evidence obtained from case-series studies without a control group
VI evidence based on the opinion of authoritative experts or of committees of experts as indicated in guidelines or a consensus
conference, or based on the opinion of the members of the workgroup responsible for this guideline
Strength of recommendations
A the performance of that particular procedure or diagnostic test is strongly recommended (it indicates a particular recommendation
supported by good quality albeit not necessarily type I or II scientific evidence)
B there is some doubt that the procedure/intervention must be always recommended, but it is thought that its execution has to
attentively be considered
C there is substantial uncertainty in favor of or against the recommendation to perform the procedure or the intervention
D performing the procedure is not recommended
E performing the procedure is strongly discouraged
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epidemic season, or preterm babies suffering from
bronchopulmonary dysplasia (BPD) ≤ 2 years of age at the
beginning of the epidemic season and requiring specific
medical therapy (oxygen support, bronchodilators, di-
uretics, corticosteroids) in the 6 months preceding the
beginning of the epidemic season, were randomized to re-
ceive palivizumab by intramuscular injection at the dose
of 15 mg/kg once a month for 5 months or placebo.
The results obtained showed a statistically significant
decrease by 55 % (from 10.6 to 4.8 %) in RSV-related
hospitalizations in subjects who received palivizumab
(n = 500) compared to subjects who received placebo
(n = 1002).
In the same year, the American Academy of Pediatrics
(AAP) [30] recommended the use of palivizumab for
prophylaxis of the RSV infection in preterm babies
of ≤ 35 weeks GA and in preterm babies presenting
with BPD.
Subsequent modifications of the AAP recommenda-
tions concerning the use of palivizumab [7, 14, 15, 31]
took into account the new epidemiological data available
concerning the incidence of hospitalizations due to
bronchiolitis in the United States, the impact of gesta-
tional age, pharmacokinetics of palivizumab and other
risk factors observed in the United States. In particular,
the AAP cited a recent prospective study [32] which
demonstrated a mean incidence of hospitalizations caused
by RSV-induced bronchiolitis which was significantly
greater in neonates < 30 weeks GA compared to more
mature preterm babies.
It must be pointed out that other data available in lit-
erature do not agree with this report, citing varying ges-
tational age cut off values as the decisive elements
underlying higher and lower risks of hospitalizations in
preterm neonates [33, 34].
For this reason, it is difficult to establish a gestational
age “threshold” differentiating between a high risk and a
lower risk in preterm neonates of less than 32 weeks GA.
It is undeniable that risks of RVS-related hospitalization
decrease as gestational age increases, but such decrease
occurs progressively and not on a step-by-step basis. All
this appears to be consistent with the position of the
Cochrane Review that, when discussing the efficacy of pali-
vizumab in preventing RSV Hospitalization, generically
states “… evidence that palivizumab is effective in reducing
incidence of severe lower respiratory tract infection in
neonates suffering from CLD or CHD and in preterm ba-
bies”, and does not touch upon gestational age subgroups
but only uses the generic definition of “preterm” [35].
A pragmatic approach might in any case take into ac-
count the coexistence of specific risk factors alongside
gestational age alone.
A recent paper by Lanari et al. [36] concerning risk
factors for RSV hospitalization and involving 2314
neonates, demonstrated that neonates of 33–34 weeks
GA have a twofold risk of hospitalization caused by
bronchiolitis infection (83 % caused by RSV) compared
to full-term babies. Moreover, the risk for neonates of
35– 37 weeks GA is one and a half times that of full-term
children. These data are confirmed by other international
studies suggesting the lack of difference in terms of risk of
hospitalization because of severe RSV infection between
these subjects and children with a lower gestational
age [34, 37–39].
It must be also noted that the Italian study states that
for the majority of hospitalizations because of RVS infec-
tion occurred during the first six months of life [36].
Lacking any clear scientific evidence, neonates of 29–35
weeks GA may receive prophylaxis, limited to the first
6 months of life, in the presence of risk factors for severe
RSV infection. The risk factors identified by various studies
are: male gender, exposure to maternal smoke and second-
hand smoke, treatment with surfactant, living with siblings
aged <10 years, attendance at daycare and births occurring
close to or during the epidemic season [39–45]. All these
risk factors were noted in the population of neonates of
33–35 weeks GA of the study carried out in Italy [36].
For infants of gestational age <29 weeks and age
≤12 months at the beginning of the epidemic season:
LEVEL OF EVIDENCE II – Strength of recom-
mendation A.
For infants of 29–35 weeks gestational age and
age ≤6 months at the beginning of the epidemic
season, prophylaxis with Palivizumab might be
taken into consideration in presence of risk condi-
tions predisposing to severe infections and/or need
for hospitalization.
[LEVEL OF EVIDENCE IV – Strength of recom-
mendation B]
There are no data supporting the use of palivizumab to
control hospital epidemics in the Neonatal Intensive Care
Unit or in Neonatology wards [14, 15].
Palivizumab prophylaxis in children with
Bronchopulmonary Dysplasia (BPD)
Bronchopulmonary dysplasia (BPD) is one of the most
significant sequelae associated with preterm births. This
definition describes the chronic lung disease that follows
a neonatal respiratory disorder [46]. BPD is defined as
the need for O2 therapy for at least 28 days after birth,
and severity is defined based on the need for respiratory
support required at 36 weeks post menstrual age [47].
There is substantial consensus concerning treatment
with Palivizumab in infants diagnosed with BPD during
their first year of life [9, 14, 15]. A recent Cochrane Col-
laboration review, that included studies on BPD pa-
tients, concluded that there is evidence that prophylaxis
with Palivizumab is effective in decreasing frequency
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of hospitalizations caused by RSV infections in these
patients [35].
Throughout the second year of life, prophylaxis with
Palivizumab is recommended for children diagnosed with
BPD who require medical therapy (oxygen, bronchodila-
tors, diuretics or chronic steroids) in the six months pre-
ceding the beginning of the epidemic season [9, 14, 15].
[LEVEL OF EVIDENCE II – Strength of recommenda-
tion A]
Palivizumab prophylaxis in children with heart
diseases
In Italy, approximately 8 neonates out of 1000 suffer
from congenital heart disease.
In 1982, MacDonald et al. reported for the first time
that children with congenital heart disease are at in-
creased risk of severe lower airway respiratory diseases
associated with RVS infections [48].
Subsequent studies confirm that these children present
an increased risk of hospitalization, with longer hospital
stays, admission to the intensive care unit, and frequent
need for oxygen therapy and mechanical ventilation for
longer periods compared to children without any risk
factors [49–53].
Cumulative data from recent published reviews, con-
firmed an increased mortality rate within patients with
significant congenital heart disease (CHD) associated
with RSV, even if mortality seems to be in marked de-
cline through years [54, 55].
Moreover, the higher risk of hospital-acquired infec-
tion caused by RVS is an unfavorable perioperative prog-
nostic factor in heart diseases with surgical indication.
In 2003 Feltes et al. [56] published data generated by a
multicenter, prospective, placebo-controlled study of the
administration of palivizumab in a population of infants
aged less than 24 months, suffering from hemodynamically
significant heart disease. The study enrolled 1287 patients
and the results obtained showed a significant 4.4 %
decrease of the hospitalization rate (9.7 % in patients who
received placebo compared to 5.3 % in patients who
received palivizumab, p = 0.003) and a decrease in morbid-
ity and in need of intensity of care. Prophylaxis with pali-
vizumab appeared to be effective also in patients with
non-cyanogenic heart disease. No case of adverse effects
of prophylaxis on surgical outcome was noted.
Based on the currently available data in literature, it may
be considered useful to recommend palivizumab prophy-
laxis for children with hemodynamically significant congeni-
tal heart disease, younger than 12 months at the beginning
of the epidemic season, and who meet the following criteria:
 Infants with cyanogenic heart disease prior to the
surgical procedure or after a palliative procedure, on
indication of the pediatric cardiologist based on the
hemodynamic status of the patient. [LEVEL OF
EVIDENCE IV – Strength of recommendation A]
 infants with non-cyanogenic heart disease on
therapy for congestive heart failure and who are
scheduled to undergo surgery; [LEVEL OF
EVIDENCE II – Strength of recommendation A]
 infants with moderate to severe pulmonary
hypertension; [LEVEL OF EVIDENCE II – Strength
of recommendation A]
 Infants with surgically repaired congenital heart
disease who continue to need therapy for congestive
heart failure; [LEVEL OF EVIDENCE II – Strength
of recommendation A]
 infants suffering from congestive cardiomyopathy on
treatment with anti-congestive medication; [LEVEL OF
EVIDENCE II – Strength of recommendation A]
 infants on the waiting list for heart transplantation
or in the post-transplantation period. [LEVEL OF
EVIDENCE II – Strength of recommendation A]
Palivizumab prophylaxis is not required in patients
with non-hemodynamically significant congenital heart
disease (for instance: ostium secundum atrial septal de-
fect, small ventricular septal defect, pulmonary artery
stenosis, uncomplicated aortic artery stenosis, mild aor-
tic coarctation, patent ductus arteriosus).
The current indications proposed by the Italian Society
of Pediatric Cardiology (SIPC) are summarized in the
intersociety document [9].
In consideration of a 58 % decrease in mean palivizu-
mab concentrations observed in children who undergo
surgical procedures with need for cardiopulmonary
bypass graft during prophylaxis, administration of an
additional dose of palivizumab after surgery is recom-
mended [32].
Children who underwent heart transplantation during
the epidemic season might benefit from palivizumab
prophylaxis also during their second year of life [14, 15].
Palivizumab prophylaxis in children belonging to
special categories: cystic fibrosis, Down syndrome,
congenital diaphragmatic hernia, neuromuscular
diseases, immunodeficiency, accumulation
disorder, esophageal atresia, lung transplantation
The Italian intersociety document and the most recent
technical report issued by the AAP concerning indica-
tions to palivizumab prophylaxis, concur that for these
categories of patients, a conclusive determination of the
risk of severe RSV infection and of the possible worsen-
ing of the underlying disease represent a true dilemma
[9, 14]. Indeed, as many of these diseases are rare, it is
not feasible to conduct randomized controlled studies
both on the actual risk of severe RSV disease and on the
effectiveness of prophylaxis with palivizumab.
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 Lung malformations or neuromuscular diseases:
in children with neuromuscular diseases or
anatomical abnormalities of the lungs with impaired
lower airway clearance, pulmonary malformations,
tracheoesophageal fistula, severe upper airway
dysfunction or tracheostomy, palivizumab
prophylaxis might be taken into consideration
during the first year of life [57–62].
 Patients with immunodeficiency: No population-
based epidemiological data are available concerning
incidence or severity of RSV infection in patients
undergoing solid organ or hematopoietic cell line
transplantation, or in patients undergoing
chemotherapy or presenting with immunodeficiency
because of other causes. Despite retrospective
studies and evaluation of clinical risks associated
with immunodeficiency, there is no evidence of a
true advantage in using palivizumab, and further
research is warranted to reach a robust conclusion
concerning indication for prophylaxis [63].
 Down Syndrome patients: The existing historic
cohort or birth cohort studies underscore a high
risk of RSV-related hospitalization in Down children,
regardless of the presence of any concomitant heart
disease. Therefore, despite the lack of randomized
controlled studies and of robust evidence generated
by prospective studies, it is legitimate to believe that
patients with Down syndrome might be considered
to be at greater risk of developing a severe form of
RSV-related bronchiolitis. Therefore, it is reasonable
to take into consideration recourse to palivizumab
prophylaxis in these patients, provided their clinical
conditions are taken into account [64–67].
 Patients with cystic fibrosis: several studies have
demonstrated a higher risk of RSV infection-related
hospitalization in patients who suffer from cystic
fibrosis [68, 69]. A study conducted by Winterstein
et al. [70] demonstrated a decreasing trend of RSV
infection hospitalizations in patients receiving
prophylaxis with palivizumab, as was already shown
by the Delphy study [71].
Despite the lack of robust scientific evidence, the ex-
pert opinion is that patients suffering from the most se-
vere forms of diseases listed above might benefit from
prophylaxis with palivizumab during the epidemic sea-
son [8, 72, 73].
[LEVEL OF EVIDENCE V - Strength of recommenda-
tion B]
Conclusions
The conclusions of these recommendations are summa-
rized in Table 2.
Italian Society of Neonatology hopes that this docu-
ment will be useful for all neonatologists and pediatri-
cians involved in the management of infants at risk of
RSV infection, and suggests that these recommendations
should be revised almost every 3–5 years on the basis of
future researches.
These recommendations are been compiled for being
used in the Italian population and they are based on
Italians epidemiological data and on other inter-society
documents.
Abbreviations
BPD: bronchopulmonary dysplasia; CHD: congenital heart disease; CLD: chronic
lung disease; CPAP: continuous positive airway pressure; GA: gestational age;
RSV: respiratory syncithial virus.
Competing interests
The authors declared the absence of competing interests.
Authors’ contributions
LB, EB and CR conceived this document, LB, EB, GC and AD revised literature
and prepared the draft of the document. ML, ADV, PM, AB, PP, SDF, LO, MS
and CR made critical revision of the article. All authors read and approved
the final manuscript. The authors did not receive funds for this review.
Acknowledgements
We are very gratefully to Liza Diana for assistance in preparing and editing paper.





Environmental hygiene prevention II A
Efficacy and safety of palivizumab prevention II A
Dose of 15 mg/Kg once a month for 5 months II A
Prophylaxis in subjects with <29 weeks GA and aged≤ 12 months at the beginning of epidemic season II A
Prophylaxis in subjects with 29–35 weeks GA and aged≤ 6 months at the beginning of epidemic season IV B
Palivizumab prophylaxis in infants with bronchopulmonary dysplasia and aged≤ 12 months at the beginning
of epidemic season, and during the second year of life in children who require medical therapy
II A
Prophylaxis in infants with severe congenital heart disease and aged≤ 12 months at the beginning of epidemic season II A
Prophylaxis in infants with cystic fibrosis, Down syndrome, congenital diaphragmatic hernia, neuromuscular diseases,
immunodeficiency, accumulation disorders, esophageal atresia, lung transplantation
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